Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "7834", "attributes": { "award_id": "1U01MD017415-01", "title": "Localized mHealth approach to boosting COVID-19 testing and vaccine literacy, access, and uptake among women with criminal legal system involvement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23654, "first_name": "YEWANDE A", "last_name": "Oladeinde", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-01-01", "end_date": "2023-11-30", "award_amount": 1262938, "principal_investigator": { "id": 23655, "first_name": "Mugur", "last_name": "Geana", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 875, "ror": "https://ror.org/036c9yv20", "name": "University of Kansas Medical Center", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23183, "first_name": "Megha", "last_name": "Ramaswamy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 875, "ror": "https://ror.org/036c9yv20", "name": "University of Kansas Medical Center", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 875, "ror": "https://ror.org/036c9yv20", "name": "University of Kansas Medical Center", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true }, "abstract": "People with criminal legal system involvement (CLSI) have experienced five times as many COVID-19 infections and have three times the risk of death compared to general population in the U.S. Heavily impacted by COVID-19 and squarely within NIH health disparities populations, people with CLSI are often poor and disproportionately from racial and ethnic minority groups. Despite the increased risk of COVID-19, we expect that only one-half of people with CLSI will get vaccinated. Ongoing COVID-19 testing in communities and among groups that are not vaccinated will be key to containing the pandemic. The messaging that COVID-19 testing will still be important may not be getting through to people who are at risk – a critical driver of disparities. Our team has a unique opportunity to boost testing literacy, access, and uptake using mobile health (mHealth) technologies (text and Web) to reach women with CLSI in community settings who are part of the existing Tri-City Cohort drawn from geographically and socio-politically diverse cities: Birmingham, AL, Kansas City, MO/KS, and Oakland, CA. This application is highly responsive to the RADx-UP Phase II call for research that tests interventions to reduce COVID-19 disparities among underserved populations. Our team is positioned to embed the proposed study into an existing Web-based women’s health literacy intervention platform (www.shewomen.org, 2R01CA181047) for women leaving jail. We are also able to immediately push the mHealth COVID-19 testing literacy intervention to 508 women we have already recruited to a three-city cervical health study of women with CLSI (R01CA226838), and to promptly make this scalable intervention widely available to people with CLSI. We will engage the women as stakeholders to study regional and individual differences in COVID-19 testing and vaccine literacy, access, and uptake. We will use findings to rapidly develop an mHealth intervention focused on COVID-19 literacy, and then push the intervention to CLSI women in the three cities to boost COVID-19 literacy, testing, access, and uptake, and vaccination. Findings will be used to develop dissemination strategies with stakeholders to push the mHealth intervention to the two million women and 11 million men who interface with the criminal legal system annually in the U.S.", "keywords": [ "Address", "Attitude", "Belief", "COVID-19", "COVID-19 disparity", "COVID-19 health disparity", "COVID-19 test", "COVID-19 testing", "COVID-19 vaccine", "Car Phone", "Cellular Phone", "Cervical", "Cities", "Communities", "Disease", "Evaluation", "Future", "General Population", "Geographic Locations", "Geography", "Goals", "Gold", "Health", "Health Technology", "Imprisonment", "Individual Differences", "Infrastructure", "Internet", "Intervention", "Jail", "Kansas", "Legal system", "Minority Groups", "Motivation", "Nature", "Online Systems", "Persons", "Phase", "Politics", "Population", "Positioning Attribute", "Public Health", "RADx Underserved Populations", "Recommendation", "Research", "Research Personnel", "Risk", "SARS-CoV-2 infection", "Sampling", "Testing", "Text", "Time", "Underserved Population", "United States National Institutes of Health", "Vaccinated", "Vaccination", "Vaccines", "Woman", "Women&apos", "s Group", "Women&apos", "s Health", "Work", "cohort", "community setting", "design", "differences in access", "dissemination strategy", "ethnic minority population", "experience", "health disparity populations", "health literacy", "high reward", "innovation", "literacy", "mHealth", "men", "mobile computing", "mortality risk", "open source", "pandemic disease", "pilot test", "post-COVID-19", "racial minority", "racism", "recruit", "regional difference", "risk perception", "secondary outcome", "testing access", "uptake", "vaccine access" ], "approved": true } }, { "type": "Grant", "id": "7392", "attributes": { "award_id": "3R42MH115539-03S2", "title": "Immersive Virtual Reality as a Tool to Improve Police Safety in Adolescents and Adults with ASD", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 23189, "first_name": "Margaret C.", "last_name": "Grabb", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-15", "end_date": "2021-08-31", "award_amount": 327942, "principal_investigator": { "id": 23190, "first_name": "Julia", "last_name": "Parish-Morris", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1574, "ror": "", "name": "FLOREO, INC.", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23191, "first_name": "Vijay", "last_name": "Ravindran", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1574, "ror": "", "name": "FLOREO, INC.", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true }, "abstract": "Floreo Technology proposes to develop the Police Safety Module (PSM), an innovative, immersive mobile virtual reality (VR) application designed to train police safety in adolescents and adults with autism spectrum disorder (ASD). ASD has been increasing in prevalence over recent years. While much attention has been paid to the causes and early diagnosis of ASD, there remains a clear need for effective interventions for the core symptoms of autism. ASD is a lifelong disorder, and adolescents and adults with ASD experience significant challenges in functional living skills. Safe community engagement, such as interaction with law enforcement officers, represents an area of concern for adolescents and young adults with ASD continuing to struggle with social communication skills. Interventions commonly used for older individuals with ASD, such as Social StoriesTM and video modeling, have not been studied specifically for efficacy in teaching police safety skills. Recent advances in VR technology have created an opportunity to explore new intervention strategies for individuals with ASD, but modern VR technology such as head-mounted displays and mobile applications have to date not been adequately investigated for feasibility or effectiveness in this population. Floreo has developed a unique product that pairs the user and a supervising therapist in an immersive virtual environment. The project team will conduct initial pilot studies on the usability and feasibility of a module dedicated to training police safety skills in adolescents and adults with ASD in an immersive virtual environment, and will then proceed to perform additional research and development on efficacy and effectiveness of the PSM in improving police safety skills.", "keywords": [ "Address", "Adolescent", "Adolescent and Young Adult", "Adult", "Area", "Attention", "Behavioral", "Communities", "Disease", "Early Diagnosis", "Educational process of instructing", "Effectiveness", "Goals", "Immersion", "Individual", "Intervention", "Law Enforcement Officers", "Modeling", "Modernization", "Pilot Projects", "Police", "Population", "Prevalence", "Public Health", "Safety", "Supervision", "Support System", "Symptoms", "Technology", "Training", "autism spectrum disorder", "design", "effective intervention", "experience", "head mounted display", "improved", "innovation", "mobile application", "research and development", "skills", "social", "social communication", "tool", "usability", "virtual reality", "virtual reality environment", "virtual reality intervention" ], "approved": true } }, { "type": "Grant", "id": "7393", "attributes": { "award_id": "3R01DA045499-03S1", "title": "Chemokine CXCL12/CXCR4 system and synthetic cathinones", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 23192, "first_name": "SUBRAMANIAM", "last_name": "Ananthan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-07-01", "end_date": "2023-04-30", "award_amount": 158500, "principal_investigator": { "id": 23193, "first_name": "SCOTT M", "last_name": "RAWLS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1445, "ror": "", "name": "TEMPLE UNIV OF THE COMMONWEALTH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23194, "first_name": "ELLEN M", "last_name": "UNTERWALD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1445, "ror": "", "name": "TEMPLE UNIV OF THE COMMONWEALTH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Human death in persons infected with SARS-CoV-2 (the virus responsible for the covid-19 pandemic) is caused by barriers dysfunction (i.e. in the pulmonary system). Angiotensin- converting enzyme 2 (ACE2) has been identified as a functional receptor of SARS-CoV-2, similarly to other coronaviruses. Surface expression of ACE2 protein was found on lung alveolar epithelial cells and enterocytes of the small intestine. In brain, ACE2 is expressed on endothelial cells, a major component of blood-brain barrier (BBB). We propose to perform a series of studies to assess the impact of SARS-CoV-2 spike protein on BBB function in the presence of cocaine as an extension of our funded research on psychostimulants and the CXCL12/CXCR4 chemokine system. First, a comprehensive series of experiments on the impact of SARS-CoV-2 spike protein in the presence and absence of cocaine on brain microvascular endothelial cells will be performed in vitro to inform on the cellular and molecular mechanism involved in altered BBB function. Included in the analysis will be measurements of cytosolic Ca2+ levels, mitochondrial reactive oxygen species, tight junctions and cytoskeletal proteins. Second, integrated fluorescence microscopy will be used to visualize and quantify changes in BBB permeability in real time in awake rats after exposure to SARS-CoV-2 spike protein. The impact of acute and chronic administration of cocaine on BBB function in the setting of SARS-CoV-2 spike protein will be determined. Finally, brain regions from rats exposed to cocaine and the spike protein will be examined for levels of pro-inflammatory cytokines and chemokines. Taken together, this series of experiments will provide novel information about the effect of the spike protein on BBB function and neuroinflammation, and its potential interactions with cocaine. We hypothesize that chronic cocaine exposure will exacerbate the negative impact of SARS-CoV-2 spike protein on BBB integrity and increase pro-inflammatory mediators in the CNS. These studies will provide the necessary groundwork to embark on a larger study of the impact of SARS-CoV-2 on cocaine behaviors and toxicities.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Area", "Award", "Behavior", "Biological Response Modifiers", "Blood - brain barrier anatomy", "Brain", "Brain region", "COVID-19", "COVID-19 pandemic", "CXCL12 gene", "CXCR4 gene", "Cessation of life", "Chemosensitization", "Chronic", "Cocaine", "Complement", "Contracts", "Coronavirus", "Cytoskeletal Proteins", "Cytoskeleton", "Electrical Resistance", "Endothelial Cells", "Endothelium", "Enterocytes", "Epithelial Cells", "Exposure to", "Female", "Fluorescence Microscopy", "Functional disorder", "Funding", "Human", "In Vitro", "Inflammation Mediators", "Inflammatory", "Inflammatory Response", "Investigation", "Laboratories", "Lung", "Measurement", "Measures", "Microbe", "Microscopy", "Mitochondria", "Molecular", "Neuraxis", "Nucleus Accumbens", "Parents", "Peptidyl-Dipeptidase A", "Permeability", "Persons", "Prefrontal Cortex", "Proteins", "Rattus", "Reactive Oxygen Species", "Research", "Resistance", "Rewards", "Role", "Series", "Small Intestines", "Surface", "System", "Testing", "Tight Junctions", "Time", "Toxic effect", "Toxin", "Ventral Tegmental Area", "Virus", "alveolar epithelium", "awake", "bath salts", "blood damage", "blood-brain barrier function", "blood-brain barrier permeabilization", "brain endothelial cell", "brain tissue", "chemokine", "cocaine exposure", "cocaine use", "cytokine", "drug seeking behavior", "experimental study", "fluorescence microscope", "frontal lobe", "in vivo", "insight", "lung injury", "male", "monolayer", "neuroinflammation", "novel", "psychostimulant", "receptor", "response", "time use" ], "approved": true } }, { "type": "Grant", "id": "9749", "attributes": { "award_id": "1R01DA054921-01A1", "title": "SARS-CoV-2 signaling and interactions with stimulant drugs of abuse via Sigma-1R: Impact on the BBB", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12691, "first_name": "Yu", "last_name": "Lin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-01", "end_date": "2027-04-30", "award_amount": 493148, "principal_investigator": { "id": 25594, "first_name": "Gabriela Cristina", "last_name": "Brailoiu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 23194, "first_name": "ELLEN M", "last_name": "UNTERWALD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1445, "ror": "", "name": "TEMPLE UNIV OF THE COMMONWEALTH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "11506", "attributes": { "award_id": "5R01DA054921-02", "title": "SARS-CoV-2 signaling and interactions with stimulant drugs of abuse via Sigma-1R: Impact on the BBB", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12691, "first_name": "Yu", "last_name": "Lin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-01", "end_date": "2027-04-30", "award_amount": 476255, "principal_investigator": { "id": 25594, "first_name": "Gabriela Cristina", "last_name": "Brailoiu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 23194, "first_name": "ELLEN M", "last_name": "UNTERWALD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1445, "ror": "", "name": "TEMPLE UNIV OF THE COMMONWEALTH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2, the virus that causes COVID-10, impacts multiple organ systems including the central nervous system. Neurological symptoms are seen in about one third of COVID-19 patients and the virus has been found in brain tissue. SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) located on cell surfaces for entry into cells, and the spike protein of the virus is the key recognition element for ACE2. ACE2 is expressed by endothelial cells of the cerebral vasculature that comprise the blood-brain barrier (BBB), the main barrier to entry of pathogens and toxins into the CNS. Recently, SARS-CoV-2 spike protein has been shown to alter BBB function using in vitro model systems. Many drugs of abuse, including psychostimulants, negatively impact BBB function as well. Therefore, it is likely that SARS-CoV-e infection in the presence of psychostimulants could result in greater damage ot the BBB, further increasing barrier permeability and resulting in CNS injury. Thus, investigation of the mechanisms underlying the interactions of SARSCoV- 2 and stimulants on the BBB is needed.", "keywords": [ "2019-nCoV", "ACE2", "Acute", "Adherens Junction", "Affect", "Binding Proteins", "Biological Models", "Blood - brain barrier anatomy", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "Calcium", "Calcium Signaling", "Cell surface", "Cells", "Cellular Stress", "Central Nervous System", "Cerebrovascular system", "Chronic", "Clinical", "Cocaine", "Contracts", "Cytoskeleton", "Data", "Dependence", "Elements", "Endothelial Cells", "Event", "Genetic", "Health", "Homeostasis", "Homologous Gene", "Impairment", "In Vitro", "Infection", "Investigation", "Jupiter", "Knowledge", "Lung", "Microbe", "Microscopy", "Microtubules", "Mitochondria", "Molecular Chaperones", "NAADP", "Neurologic Symptoms", "Organ", "Pathway interactions", "Permeability", "Persons", "Process", "Proteins", "Rattus", "Reactive Oxygen Species", "Reporting", "Research", "Role", "SARS coronavirus", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "Second Messenger Systems", "Signal Transduction", "Signaling Protein", "Stimulant", "Structure", "Testing", "Tight Junctions", "Toxin", "Vascular Endothelial Cell", "Viral", "Viral Proteins", "Virus", "antagonist", "blood damage", "blood-brain barrier disruption", "blood-brain barrier function", "blood-brain barrier permeabilization", "body system", "brain endothelial cell", "brain tissue", "capsule", "central nervous system injury", "cocaine exposure", "coronavirus disease", "drug of abuse", "electric impedance", "in vitro Model", "in vivo", "insight", "novel therapeutic intervention", "pathogen", "pharmacologic", "psychostimulant", "real time monitoring", "receptor", "sigma-1 receptor", "stimulant use disorder", "trafficking" ], "approved": true } }, { "type": "Grant", "id": "7396", "attributes": { "award_id": "3U19AI128913-03S2", "title": "Mapping Immune Responses to CMV in Renal Transplant Recipients - Mechanistic Assays Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23197, "first_name": "MARK ANDREW", "last_name": "ROBIEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-19", "end_date": "2021-07-31", "award_amount": 222841, "principal_investigator": { "id": 23198, "first_name": "ELAINE F", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23199, "first_name": "Minnie M", "last_name": "Sarwal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 clinical syndrome caused by the SARS-CoV-2 virus has the potential to cause significant morbidity and mortality in previously healthy patients. A significant observation is that although this infection may result in a self-limiting upper respiratory infection or mild pneumonia in some patients, other patients experience progression of respiratory symptoms to requirement of intubation for mechanical respiratory support and death due to severe respiratory failure. This clinical observation strongly suggests that differences in host immunologic response are the determinative factor in clinical outcome. We hypothesize that the proposed systems immunology, biostatistical and computational modeling approaches, coupled with detailed clinical phenotype of hospitalized COVID-19 patients will provide a new framework to interpret the interplay between SARS-CoV-2 virus and the host, and the relationship with clinical outcome. Project 1 will assess the frequency and function of SARS-CoV-2 virus antigen specific T cells and evaluate their breadth and clonality of their TCR repertoire with clinical outcome. Project 2 will determine epigenetic signatures of the immune response to the SARS-CoV-2 virus across short, middle and long-term times and identify DNA methylation- based markers of anti-viral immunity and clinical outcome. With this approach, we will create a unique resource of highly annotated longitudinal data on SARS-CoV-2 virus infection, which will enable the development of novel diagnostic strategies and therapeutics to treat or prevent SARS-CoV-2 virus infection.", "keywords": [ "2019-nCoV", "Biological Assay", "Biometry", "COVID-19", "Cessation of life", "Characteristics", "Clinical", "Clonality", "Computer Models", "Coupled", "Critical Illness", "Cytomegalovirus", "DNA Methylation", "Data", "Development", "Disease", "Epigenetic Process", "Frequencies", "Immune", "Immune response", "Immunologics", "Immunology", "Infection", "Intubation", "Kidney Transplantation", "Measures", "Mechanics", "Morbidity - disease rate", "Outcome", "Patients", "Pneumonia", "Resources", "Respiratory Failure", "Respiratory Signs and Symptoms", "Severity of illness", "Syndrome", "System", "T-cell receptor repertoire", "Technology", "Therapeutic", "Time", "Transplant Recipients", "Upper Respiratory Infections", "Viral Antigens", "Virus", "Virus Diseases", "antigen-specific T cells", "antiviral immunity", "base", "clinical phenotype", "experience", "immune function", "mortality", "novel", "novel diagnostics", "prevent", "respiratory" ], "approved": true } }, { "type": "Grant", "id": "7397", "attributes": { "award_id": "3U19AI128913-03S1", "title": "Mapping Immune Responses to CMV in Renal Transplant Recipients - Clinical Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23197, "first_name": "MARK ANDREW", "last_name": "ROBIEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-18", "end_date": "2021-07-31", "award_amount": 869489, "principal_investigator": { "id": 23198, "first_name": "ELAINE F", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23199, "first_name": "Minnie M", "last_name": "Sarwal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 clinical syndrome caused by the SARS-CoV-2 virus has the potential to cause significant morbidity and mortality in previously healthy patients. A significant observation is that although this infection may result in a self-limiting upper respiratory infection or mild pneumonia in some patients, other patients experience progression of respiratory symptoms to requirement of intubation for mechanical respiratory support and death due to severe respiratory failure. This clinical observation strongly suggests that differences in host immunologic response are the determinative factor in clinical outcome. We hypothesize that the proposed systems immunology, biostatistical and computational modeling approaches, coupled with detailed clinical phenotype of hospitalized COVID-19 patients will provide a new framework to interpret the interplay between SARS-CoV-2 virus and the host, and the relationship with clinical outcome. Project 1 will assess the frequency and function of SARS-CoV-2 virus antigen specific T cells and evaluate their breadth and clonality of their TCR repertoire with clinical outcome. Project 2 will determine epigenetic signatures of the immune response to the SARS-CoV-2 virus across short, middle and long-term times and identify DNA methylation- based markers of anti-viral immunity and clinical outcome. With this approach, we will create a unique resource of highly annotated longitudinal data on SARS-CoV-2 virus infection, which will enable the development of novel diagnostic strategies and therapeutics to treat or prevent SARS-CoV-2 virus infection.", "keywords": [ "2019-nCoV", "Biological Assay", "Biometry", "COVID-19", "Cessation of life", "Characteristics", "Clinical", "Clonality", "Computer Models", "Coupled", "Critical Illness", "Cytomegalovirus", "DNA Methylation", "Data", "Development", "Disease", "Epigenetic Process", "Frequencies", "Immune", "Immune response", "Immunologics", "Immunology", "Infection", "Intubation", "Kidney Transplantation", "Measures", "Mechanics", "Morbidity - disease rate", "Outcome", "Patients", "Pneumonia", "Resources", "Respiratory Failure", "Respiratory Signs and Symptoms", "Severity of illness", "Syndrome", "System", "T-cell receptor repertoire", "Technology", "Therapeutic", "Time", "Transplant Recipients", "Upper Respiratory Infections", "Viral Antigens", "Virus", "Virus Diseases", "antigen-specific T cells", "antiviral immunity", "base", "clinical phenotype", "experience", "immune function", "mortality", "novel", "novel diagnostics", "prevent", "respiratory" ], "approved": true } }, { "type": "Grant", "id": "7398", "attributes": { "award_id": "3U19AI128913-03S3", "title": "Mapping Immune Responses to CMV in Renal Transplant Recipients - Mechanistic Assays Core (UCSF)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23197, "first_name": "MARK ANDREW", "last_name": "ROBIEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-22", "end_date": "2021-07-31", "award_amount": 208861, "principal_investigator": { "id": 23198, "first_name": "ELAINE F", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23199, "first_name": "Minnie M", "last_name": "Sarwal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 clinical syndrome caused by the SARS-CoV-2 virus has the potential to cause significant morbidity and mortality in previously healthy patients. A significant observation is that although this infection may result in a self-limiting upper respiratory infection or mild pneumonia in some patients, other patients experience progression of respiratory symptoms to requirement of intubation for mechanical respiratory support and death due to severe respiratory failure. This clinical observation strongly suggests that differences in host immunologic response are the determinative factor in clinical outcome. We hypothesize that the proposed systems immunology, biostatistical and computational modeling approaches, coupled with detailed clinical phenotype of hospitalized COVID-19 patients will provide a new framework to interpret the interplay between SARS-CoV-2 virus and the host, and the relationship with clinical outcome. Project 1 will assess the frequency and function of SARS-CoV-2 virus antigen specific T cells and evaluate their breadth and clonality of their TCR repertoire with clinical outcome. Project 2 will determine epigenetic signatures of the immune response to the SARS-CoV-2 virus across short, middle and long-term times and identify DNA methylation- based markers of anti-viral immunity and clinical outcome. With this approach, we will create a unique resource of highly annotated longitudinal data on SARS-CoV-2 virus infection, which will enable the development of novel diagnostic strategies and therapeutics to treat or prevent SARS-CoV-2 virus infection.", "keywords": [ "2019-nCoV", "Affect", "Antibodies", "Antibody Repertoire", "B-Lymphocytes", "Biological Assay", "Biological Markers", "Biometry", "Blood specimen", "COVID-19", "CXCL10 gene", "Cells", "Cessation of life", "Characteristics", "Clinical", "Clinical Data", "Clonality", "Collaborations", "Communities", "Computer Models", "Coupled", "Creatinine", "Critical Illness", "Cytomegalovirus", "Cytosine", "DNA", "DNA Methylation", "Data", "Development", "Disease", "Disease Outbreaks", "Disease Progression", "Early Diagnosis", "Enrollment", "Epigenetic Process", "Evaluation", "Fatality rate", "Frequencies", "Genetic Recombination", "Grant", "Immune", "Immune response", "Immunoglobulins", "Immunologics", "Immunology", "Immunophenotyping", "Infection", "Injury to Kidney", "Integration Host Factors", "Intubation", "Kidney", "Kidney Transplantation", "Letters", "Link", "Lung", "Measures", "Mechanics", "Medical", "Meta-Analysis", "Methylation", "Morbidity - disease rate", "Names", "National Institute of Allergy and Infectious Disease", "Observational Study", "Organ", "Outcome", "Pathogenesis", "Pathogenicity", "Patients", "Persons", "Phenotype", "Plasma", "Pneumonia", "Population", "Predisposing Factor", "Proteins", "Research Personnel", "Resources", "Respiratory Failure", "Respiratory Signs and Symptoms", "Risk", "Sampling", "Schedule", "Series", "Severities", "Severity of illness", "Syndrome", "System", "T-Cell Receptor", "T-Lymphocyte", "T-cell receptor repertoire", "Technology", "Testing", "Therapeutic", "Time", "Transplant Recipients", "Upper Respiratory Infections", "Urine", "V(D)J Recombination", "Variant", "Viral Antigens", "Virus", "Virus Diseases", "antigen-specific T cells", "antiviral immunity", "base", "clinical phenotype", "clinical research site", "cohort", "design", "experience", "global health", "immune function", "immunogenicity", "mortality", "novel", "novel diagnostics", "organ injury", "outcome prediction", "parent grant", "prevent", "protein metabolite", "renal damage", "respiratory", "response", "sample collection", "sulfated glycoprotein 2" ], "approved": true } }, { "type": "Grant", "id": "7399", "attributes": { "award_id": "3U19AI128913-04S1", "title": "Mapping Immune Responses to CMV in Renal Transplant Recipients - Transplant Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23197, "first_name": "MARK ANDREW", "last_name": "ROBIEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-08-01", "end_date": "2022-07-31", "award_amount": 2132116, "principal_investigator": { "id": 23198, "first_name": "ELAINE F", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23199, "first_name": "Minnie M", "last_name": "Sarwal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 virus infection and associated COVID-19 disease has caused unparalleled global morbidity and mortality in previously healthy patients, with over 4 million cases and 150,000 deaths in the US alone. Older patients, who experience immune dysfunction associated with aging, and patients with underlying health issues, such as chronic kidney disease, have been inequitably burdened by COVID-19. Understanding correlates of protection against SARS-CoV-2 infection and why these immunocompromised patients apparently possess deficiencies in generating these protective immune responses is critical to developing clinical practices for these at-risk populations. To address this fundamental knowledge gap, this study will characterize the natural immune response to SARS-CoV-2 virus infection in immunocompromised patients and determine whether immunity is long-lasting. Specifically, we will evaluate the quantity and quality of antibodies against SARS-CoV-2 and their relationship to frequency and functionality of SARS-CoV-2-specific T cells, therefore generating a complete picture of the adaptive immune response to SARS-CoV-2 in immunocompromised patients. To achieve our goal, we have utilized four kidney transplant centers within the University of California to establish a cohort of 2500 patients with end-stage renal disease (ESRD) awaiting transplant and 2000 renal transplant recipients with banked pre- and post-COVID-19 pandemic sera across a highly racially and ethnically diverse population, of which 40% are from minority populations that have been inequitably burdened by COVID-19. We will screen for exposure to SARS-CoV-2 in the complete cohort of 4500 patients, enrolling 100 ESRD and 76 renal transplant recipients with evidence of SARS-CoV-2-specific antibodies, based on a recent population seroprevalence estimate of 4% in Los Angeles. We will additionally recruit matched patients without evidence of SARS-CoV-2-specific antibodies. Antibody titer, isotype, subclass, avidity, infection neutralization and ability to interface with cell-mediated immunity will be determined at baseline with longitudinal follow-up 3-6 month and 9- 12 months later to assess longevity of humoral immune responses to SARS-CoV-2. Similarly, we will delineate the frequency, phenotype and longevity of SARS-CoV-2-specific cellular immune responses. This study will generate an extensive repository of clinical phenotypes, outcomes, and high-dimensional blood and urine profiling data on longitudinal samples of patients with and without exposure to SARS-CoV-2 in the California transplant population, providing an invaluable resource for the research community in understanding immunity to SARS-CoV-2. Utilizing state-of-the-art biostatistics and computational approaches, we will integrate high-dimensional data of humoral and cellular immune responses to develop models of combined adaptive immune profiles following SARS-CoV-2 exposure and assess their longevity and likelihood of protecting upon re-exposure.", "keywords": [ "2019-nCoV", "Address", "Administrative Supplement", "Aging", "Antibodies", "Antibody Response", "Antibody titer measurement", "Avidity", "Bioinformatics", "Biometry", "Blood", "CD8-Positive T-Lymphocytes", "COVID-19", "COVID-19 pandemic", "California", "Cancer Patient", "Cellular Immunity", "Cessation of life", "Chronic Kidney Failure", "Clinical", "Clinical Trials", "Communities", "Computer Models", "Cytomegalovirus", "Data", "Disease", "End stage renal failure", "Enrollment", "Evolution", "Exposure to", "Frequencies", "Goals", "Health", "Human", "Humoral Immunities", "Immune", "Immune System Diseases", "Immune response", "Immunity", "Immunobiology", "Immunocompromised Host", "Infection", "Kidney Transplantation", "Kinetics", "Knowledge", "Link", "Longevity", "Los Angeles", "Maintenance", "Minority", "Modeling", "Molecular Profiling", "Morbidity - disease rate", "Outcome", "Patients", "Phenotype", "Population", "Population Heterogeneity", "Populations at Risk", "Research Proposals", "Resources", "Risk", "Sampling", "Seroprevalences", "Suggestion", "Syndrome", "T cell response", "T-Lymphocyte", "T-cell receptor repertoire", "Technology", "Transplant Recipients", "Transplantation", "Universities", "Urine", "Vaccine Design", "Virus", "Virus Diseases", "Work", "adaptive immune response", "antigen-specific T cells", "base", "clinical phenotype", "clinical practice", "cohort", "comorbidity", "ethnic diversity", "experience", "follow-up", "high dimensionality", "high risk", "improved", "insight", "mortality", "multidimensional data", "multiple omics", "novel", "older patient", "pandemic disease", "pathogen", "post-transplant", "racial diversity", "recruit", "repository", "response", "transplant centers" ], "approved": true } }, { "type": "Grant", "id": "7445", "attributes": { "award_id": "3R01DK109720-04S1", "title": "The KIDCOV Study: Assessment of Kidney Injury and Associated Risk Factors for SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 22545, "first_name": "KEVIN E", "last_name": "Chan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-04-01", "end_date": "2022-03-31", "award_amount": 459623, "principal_investigator": { "id": 23237, "first_name": "Jochen", "last_name": "Reiser", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23199, "first_name": "Minnie M", "last_name": "Sarwal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "From early studies and published reports indicate kidney injury is one of the manifestations of COVID-19. The human kidney is a direct target of the virus, as the angiotensin-converting enzyme 2 (ACE2), a putative receptor for SARS-CoV-2, is highly expressed in the kidney tubules. As direct evidence of the virus localizing to the kidney, SARS-CoV-2 viral RNA can be observed in urine and kidney tissue from patients with COVID-19. Kidney injury can result in acute kidney injury in ~60% of hospitalized patients. The incidence, prevalence and risk factors of kidney injury in patients with mild/ asymptomatic out-patient COVID-19 disease is as yet unknown. This forms a large cohort of SARS-CoV-2 infected patients in the community world-wide. We propose in this supplement to the parent RO1 that examines suPAR and other circulating factors in FSGS disease, that urinary suPAR and other urine biomarkers that comprise a novel highly sensitive and quantitative assay (the Kidney Injury Test), can provide an assessment of the incidence and prevalence of kidney damage in COVID-19 by home-based urine testing, independent of any blood test requirement. In this study, we are hypothesizing that risk of kidney injury in COVID-19 disease, also varies by race/ethnicity and other demographic factors, is exacerbated by COVID-19 infection, and is more severe in those with a history of or risk factors of kidney disease. We have made careful selection of 7 large academic medical center study sites, in 3 states, to address these questions in the KIDCOV prospective, multi-center study. To test the hypothesis and to achieve the aim of the KIDCOV project, we will perform the study in three stages:. In the first stage, we will enroll outpatient COVID-19 positive patients. COVID-19 positive patients will be enrolled from academic medical centers in California (University of California, 5 campuses), Michigan (University of Michigan) and Illinois (Rush University). Prospective matched cohorts of COVID positive and COVID negative individuals, balanced by race/ethnicity, will be identified through EMRs and contacted by phone within 2 weeks of screening to provide consent and complete a baseline questionnaire. In the second stage, over the following 12 months, urine samples will be collected and shipped for the assessment of specific urinary markers at UCSF central lab (cell-free DNA (cfDNA), methylation of cell-free DNA (mcf-DNA), clusterin, CXCL10, protein and creatinine) to compute a validated Kidney Injury Test (KIT)-Score for sensitive assessment of early kidney damage. Acute kidney injury markers, NGAL, KIM-1 and suPAR will also be quantitated in urine as correlates of kidney damage with the KIT-Score. In the final phase, data analysis will be done to compare the proportion of patients with kidney injury between the COVID-19 positive and COVID-19 negative groups and identify groups at higher risk for kidney injury, with primary focus on COVID19 status, history/risk factors of prior kidney disease, and geographic, demographic and ethnic variation.", "keywords": [ "2019-nCoV", "Academic Medical Centers", "Acute", "Acute Kidney Failure", "Acute Renal Failure with Renal Papillary Necrosis", "Address", "African American", "Alaska Native", "American Indians", "Asians", "Asses", "Back", "Biological Assay", "Biological Markers", "Blood Tests", "COVID-19", "COVID-19 pandemic", "CXCL10 gene", "California", "Cells", "Clinical", "Cohort Studies", "Collection", "Communities", "Computerized Medical Record", "Consent", "Creatinine", "Custom", "DNA", "DNA Methylation", "Data", "Data Analyses", "Data Coordinating Center", "Demographic Factors", "Detection", "Diagnosis", "Disease", "Electronic Health Record", "Enrollment", "Ethnic Origin", "Evolution", "Focal Segmental Glomerulosclerosis", "Geography", "Health Status", "High Prevalence", "Home environment", "Human", "Illinois", "Incidence", "Individual", "Infection", "Injury to Kidney", "Island", "Kidney", "Kidney Diseases", "LCN2 gene", "Low Prevalence", "Michigan", "Minority", "Multicenter Studies", "Native Hawaiian", "Needles", "Outpatients", "Parents", "Participant", "Patients", "Peptidyl-Dipeptidase A", "Phase", "Population", "Population Density", "Prevalence", "Prospective Studies", "Prospective cohort", "Proteins", "Proteinuria", "Publishing", "Questionnaires", "Race", "Recording of previous events", "Renal tubule structure", "Reporting", "Research", "Research Design", "Risk", "Risk Factors", "Running", "Sampling", "Serum", "Ships", "Site", "Social Distance", "Specific qualifier value", "Sterility", "Symptoms", "Telephone", "Temperature", "Test Result", "Testing", "Time", "Tissues", "Universities", "Urine", "Variant", "Virus", "Virus Diseases", "base", "cell free DNA", "cohort", "comorbidity", "coronavirus disease", "cytokine release syndrome", "demographics", "epidemiologic data", "ethnic diversity", "follow-up", "high risk", "infection risk", "innovative technologies", "novel", "prospective", "receptor", "renal damage", "screening", "standard of care", "sulfated glycoprotein 2", "urinary", "viral RNA" ], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1419, "count": 14184 } } }